Arcturus Therapeutics Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $29.4M-80.7% YoYTTM through 30 Jun 2026
Net Income -$93.3MTTM through 30 Jun 2026
Free Cash Flow -$72.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -339.0% |
| Operating Margin | -1,403.7% |
| Net Margin | -317.6% |
Returns
-41.1%ROE
-32.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.31x
Net Debt-$211.4Mnet cash position
Cash & Equivalents$191.5M
Quality Metrics
Altman Z-Score0.64
Piotroski F-Score1 / 9
FCF Margin-248.0%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $82M
Diluted EPS-$3.33TTMFY2025: $-2.40
Dividend
No dividend
Capital Allocation
Capex Intensity0.3%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.